deferoxamine has been researched along with Ischemia in 67 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
Excerpt | Relevance | Reference |
---|---|---|
"Twenty-three patients with limb ischemia and referred for below the knee amputations were randomized for treatment: group 1, 7 patients received only a saline injection; group 2, 9 received intramuscular injection of fibrin and group 3, 7 received the fibrin composition with deferoxamine and added VEGF(165)." | 9.10 | Therapeutic angiogenesis for patients with limb ischemia by utilization of fibrin meshwork. Pilot randomized controlled study. ( Beridze, N; Kipiani, K; Kipshidze, N; Kipshidze, NN; Moses, J; Roubin, G; Shehzad, MZ; Tsapenko, M, 2003) |
"We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 7.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
"We evaluated the activities of mitochondrial respiratory chain complexes in the brain of rats after renal ischemia and the effect of administration of the antioxidants N-acetylcysteine (NAC) and deferoxamine (DFX)." | 7.76 | Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by N-acetylcysteine and deferoxamine. ( Barbosa, PR; Cardoso, MR; Dal-Pizzol, F; Daufenbach, JF; Gonçalves, CL; Machado, RA; Rezin, GT; Roza, CA; Scaini, G; Schuck, PF; Streck, EL, 2010) |
" Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme." | 7.74 | Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration. ( Burigo, M; Constantino, L; Dal-Pizzol, F; Di-Pietro, PB; Dias, ML; Machado, RA; Scaini, G; Streck, EL, 2008) |
") injection of a modified fibrin meshwork plus deferoxamine was tested in a rabbit model of acute hind-limb ischemia." | 7.72 | Deferoxamine-fibrin accelerates angiogenesis in a rabbit model of peripheral ischemia. ( Akhtar, M; Baibekov, I; Bajwa, T; Chekanov, VS; Hare, J; Karakozov, P; Nikolaychik, V; Tchekanov, G; Zargarian, M, 2003) |
"Pretreatment with gadolinium chloride, an inhibitor of Kupffer cell function, significantly decreased LDH and PNP efflux during reperfusion by approximately 60% and 50%, respectively." | 5.31 | Antioxidants and gadolinium chloride attenuate hepatic parenchymal and endothelial cell injury induced by low flow ischemia and reperfusion in perfused rat livers. ( Bailey, SM; Reinke, LA, 2000) |
"Twenty-three patients with limb ischemia and referred for below the knee amputations were randomized for treatment: group 1, 7 patients received only a saline injection; group 2, 9 received intramuscular injection of fibrin and group 3, 7 received the fibrin composition with deferoxamine and added VEGF(165)." | 5.10 | Therapeutic angiogenesis for patients with limb ischemia by utilization of fibrin meshwork. Pilot randomized controlled study. ( Beridze, N; Kipiani, K; Kipshidze, N; Kipshidze, NN; Moses, J; Roubin, G; Shehzad, MZ; Tsapenko, M, 2003) |
"Although the systemic administration of deferoxamine (DFO) is protective in experimental models of normal ischemic flap and diabetic wound, its effect on diabetic flap ischemia using a local injection remains unknown." | 3.80 | Local injection of deferoxamine improves neovascularization in ischemic diabetic random flap by increasing HIF-1α and VEGF expression. ( Cai, Y; Cui, L; Li, G; Wang, C; Xiong, Z; Zhang, Y, 2014) |
"We have previously shown that deferoxamine (DFO) infusion protected myocardium against reperfusion injury in patients undergoing open heart surgery, and reduced brain edema, intracranial pressure, and lung injury in pigs with acute hepatic ischemia (AHI)." | 3.78 | Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs. ( Arkadopoulos, N; Degiannis, D; Demonakou, M; Kaklamanis, L; Kostopanagiotou, G; Siasiakou, S; Smyrniotis, V; Vlahakos, D, 2012) |
"We evaluated the activities of mitochondrial respiratory chain complexes in the brain of rats after renal ischemia and the effect of administration of the antioxidants N-acetylcysteine (NAC) and deferoxamine (DFX)." | 3.76 | Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by N-acetylcysteine and deferoxamine. ( Barbosa, PR; Cardoso, MR; Dal-Pizzol, F; Daufenbach, JF; Gonçalves, CL; Machado, RA; Rezin, GT; Roza, CA; Scaini, G; Schuck, PF; Streck, EL, 2010) |
" Considering that creatine kinase (CK) is important for brain energy homeostasis and is inhibited by free radicals, and that oxidative stress is probably involved in the pathogenesis of uremic encephalopathy, we measured CK activity (hippocampus, striatum, cerebellum, cerebral cortex and prefrontal cortex) in brain if rats submitted to renal ischemia and the effect of administration of antioxidants (N-acetylcysteine, NAC and deferoxamine, DFX) on this enzyme." | 3.74 | Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration. ( Burigo, M; Constantino, L; Dal-Pizzol, F; Di-Pietro, PB; Dias, ML; Machado, RA; Scaini, G; Streck, EL, 2008) |
" The objective of this study was to investigate the efficacy of the iron chelator deferoxamine mesylate in preventing skeletal muscle ischemia." | 3.72 | Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model. ( Adamian, M; Akhtar, M; Chekanov, VS; Dangas, G; Kipshidze, N; Leon, MB; Maternowski, MA; Mehran, R; Moses, J; Nikolaychik, V, 2003) |
") injection of a modified fibrin meshwork plus deferoxamine was tested in a rabbit model of acute hind-limb ischemia." | 3.72 | Deferoxamine-fibrin accelerates angiogenesis in a rabbit model of peripheral ischemia. ( Akhtar, M; Baibekov, I; Bajwa, T; Chekanov, VS; Hare, J; Karakozov, P; Nikolaychik, V; Tchekanov, G; Zargarian, M, 2003) |
"A previous study indicated that hydroxyl radicals are generated in the cat retina during the early reperfusion phase after 90 minutes of ischemia." | 3.69 | Protection of the transiently ischemic cat retina by zinc-desferrioxamine. ( Averbukh, E; Berenshtein, E; Kitrossky, N; Ophir, A, 1994) |
" To evaluate whether iron chelation with deferoxamine interrupts this process in postischemic skeletal muscle, high-grade partial hindlimb ischemia was created in Sprague-Dawley rats by clamping the infrarenal aorta for 90 min, after which period the clamp was removed and flow was reestablished for 60 min." | 3.68 | Deferoxamine prevents lipid peroxidation and attenuates reoxygenation injury in postischemic skeletal muscle. ( Fantini, GA; Yoshioka, T, 1993) |
"A series of experiments was performed to characterize the effects of tissue trauma, extracellular calcium concentration, and prior ischemia on oxidative stress, measured by the accumulation of malondialdehyde-like materials (MDA-LM) in slices of rat liver." | 3.68 | Traumatic versus postischemic induction of oxidative stress in rat liver. ( Babbs, CF; Pham, J; Salaris, SC, 1993) |
" To assess the role of iron-catalyzed oxidant production in ischemia-reperfusion injury, we examined the influence of deferoxamine (an iron chelator) and apotransferrin (iron transporting protein) on the increased intestinal vascular permeability produced by 1 h of ischemia and reperfusion." | 3.67 | A role for iron in oxidant-mediated ischemic injury to intestinal microvasculature. ( Granger, DN; Grisham, MB; Hernandez, LA, 1987) |
"Ischemia/reperfusion injury is a leading cause of acute renal failure triggering an inflammatory response associated with infiltrating macrophages, which determine disease outcome." | 1.38 | Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2. ( Hotter, G; Hughes, J; Jung, M; Kluth, DC; Pérez-Ladaga, A; Sola, A; Viñas, JL; Vinuesa, E, 2012) |
"Deferoxamine treatment prevented these effects, while the usefulness of L-arginine remained doubtful." | 1.31 | Effect of deferoxamine and L-arginine treatment on lipid peroxidation in an intestinal ischaemia-reperfusion model in rats. ( Balogh, N; Gaál, T; Krausz, F; Lévai, P; Ribiczeyné, PS; Vajdovich, P, 2002) |
"Pretreatment with gadolinium chloride, an inhibitor of Kupffer cell function, significantly decreased LDH and PNP efflux during reperfusion by approximately 60% and 50%, respectively." | 1.31 | Antioxidants and gadolinium chloride attenuate hepatic parenchymal and endothelial cell injury induced by low flow ischemia and reperfusion in perfused rat livers. ( Bailey, SM; Reinke, LA, 2000) |
" These findings were correlated with the dosage of vitamin E since the vitamin E content was greatly reduced by 46." | 1.29 | Preservation of cortical microcirculation after kidney ischemia-reperfusion: value of an iron chelator. ( Defraigne, JO; Detry, O; Franssen, C; Limet, R; Meurisse, M; Pincemail, J, 1994) |
"Treatment with gadolinium chloride (GdCl3) selectively reduced the capacity of Kupffer cells to generate superoxide by 65% and attenuated liver injury by 73% at 4 h and 58-69% at 24 h." | 1.29 | Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia. ( Farhood, A; Fisher, MA; Jaeschke, H; Liu, P; McGuire, GM; Smith, CW, 1995) |
"Free radical-mediated reperfusion injury has been demonstrated in ischemic neonatal bowel necrosis, but the mechanism of injury remains elusive." | 1.29 | Prevention of postischemic injury in immature intestine by deferoxamine. ( Cobb, LM; Lelli, JL; Pradhan, S, 1993) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 13 (19.40) | 18.7374 |
1990's | 29 (43.28) | 18.2507 |
2000's | 11 (16.42) | 29.6817 |
2010's | 11 (16.42) | 24.3611 |
2020's | 3 (4.48) | 2.80 |
Authors | Studies |
---|---|
Xu, D | 1 |
Gan, K | 1 |
Wang, Y | 3 |
Wu, Z | 1 |
Zhang, S | 1 |
Peng, Y | 1 |
Fang, X | 1 |
Wei, H | 1 |
Zhang, Y | 2 |
Ma, W | 1 |
Chen, J | 1 |
Yu, X | 1 |
Ma, X | 1 |
Lyu, J | 1 |
Jiang, N | 1 |
Lu, Y | 1 |
Liao, Y | 1 |
Wang, K | 1 |
Yu, W | 1 |
Huang, Y | 1 |
He, N | 1 |
Kang, Q | 1 |
Shen, D | 1 |
Wang, X | 1 |
Chen, L | 1 |
Tang, LJ | 1 |
Luo, XJ | 1 |
Tu, H | 1 |
Chen, H | 1 |
Xiong, XM | 1 |
Li, NS | 1 |
Peng, J | 1 |
Jiang, X | 1 |
Malkovskiy, AV | 1 |
Tian, W | 1 |
Sung, YK | 1 |
Sun, W | 1 |
Hsu, JL | 1 |
Manickam, S | 1 |
Wagh, D | 1 |
Joubert, LM | 1 |
Semenza, GL | 1 |
Rajadas, J | 1 |
Nicolls, MR | 1 |
Saito, T | 1 |
Tabata, Y | 1 |
Wang, C | 1 |
Cai, Y | 1 |
Xiong, Z | 1 |
Li, G | 1 |
Cui, L | 1 |
Du, Z | 1 |
Zan, T | 1 |
Huang, X | 1 |
Sheng, L | 2 |
Li, H | 3 |
Li, Q | 2 |
Zhu, Y | 1 |
Zhang, L | 1 |
Gidday, JM | 1 |
Weng, R | 1 |
Yang, M | 1 |
Barbosa, PR | 1 |
Cardoso, MR | 1 |
Daufenbach, JF | 1 |
Gonçalves, CL | 1 |
Machado, RA | 2 |
Roza, CA | 1 |
Scaini, G | 2 |
Rezin, GT | 1 |
Schuck, PF | 1 |
Dal-Pizzol, F | 2 |
Streck, EL | 2 |
Ikeda, Y | 1 |
Tajima, S | 1 |
Yoshida, S | 1 |
Yamano, N | 1 |
Kihira, Y | 1 |
Ishizawa, K | 1 |
Aihara, K | 1 |
Tomita, S | 1 |
Tsuchiya, K | 1 |
Tamaki, T | 1 |
Vlahakos, D | 1 |
Arkadopoulos, N | 1 |
Kostopanagiotou, G | 1 |
Siasiakou, S | 1 |
Kaklamanis, L | 1 |
Degiannis, D | 1 |
Demonakou, M | 1 |
Smyrniotis, V | 1 |
Jung, M | 1 |
Sola, A | 1 |
Hughes, J | 1 |
Kluth, DC | 1 |
Vinuesa, E | 1 |
Viñas, JL | 1 |
Pérez-Ladaga, A | 1 |
Hotter, G | 1 |
Hastings, CL | 1 |
Kelly, HM | 1 |
Murphy, MJ | 1 |
Barry, FP | 1 |
O'Brien, FJ | 1 |
Duffy, GP | 1 |
Balogh, N | 1 |
Krausz, F | 1 |
Lévai, P | 1 |
Ribiczeyné, PS | 1 |
Vajdovich, P | 1 |
Gaál, T | 1 |
Chekanov, VS | 3 |
Nikolaychik, V | 3 |
Maternowski, MA | 1 |
Mehran, R | 1 |
Leon, MB | 1 |
Adamian, M | 1 |
Moses, J | 2 |
Dangas, G | 1 |
Kipshidze, N | 2 |
Akhtar, M | 2 |
Huang, H | 1 |
He, Z | 1 |
Roberts, LJ | 1 |
Salahudeen, AK | 1 |
Zargarian, M | 1 |
Baibekov, I | 1 |
Karakozov, P | 1 |
Tchekanov, G | 1 |
Hare, J | 1 |
Bajwa, T | 1 |
Kipiani, K | 1 |
Beridze, N | 1 |
Roubin, G | 1 |
Tsapenko, M | 1 |
Shehzad, MZ | 1 |
Kipshidze, NN | 1 |
Di-Pietro, PB | 1 |
Dias, ML | 1 |
Burigo, M | 1 |
Constantino, L | 1 |
Franssen, C | 4 |
Defraigne, JO | 4 |
Detry, O | 4 |
Pincemail, J | 4 |
Deby, C | 1 |
Lamy, M | 2 |
Lindnér, P | 1 |
Naredi, P | 1 |
Peterson, A | 1 |
Hafström, L | 1 |
Cameron, NE | 1 |
Cotter, MA | 1 |
Gonzalez-Fajardo, JA | 1 |
Fernandez, L | 1 |
Alvarez, T | 1 |
Vaquero, C | 1 |
Ozaki, M | 2 |
Fuchinoue, S | 2 |
Teraoka, S | 2 |
Ota, K | 2 |
Reuter, DG | 1 |
Tacker, WA | 1 |
Babbs, CF | 3 |
Badylak, SF | 1 |
Voorhees, WD | 1 |
Konrad, PE | 1 |
Meurisse, M | 3 |
Limet, R | 3 |
Liu, P | 1 |
McGuire, GM | 1 |
Fisher, MA | 1 |
Farhood, A | 1 |
Smith, CW | 1 |
Jaeschke, H | 1 |
Ophir, A | 1 |
Berenshtein, E | 1 |
Kitrossky, N | 1 |
Averbukh, E | 1 |
Gower, JD | 3 |
Ambrose, IJ | 1 |
Manek, S | 1 |
Bright, J | 1 |
Dobbin, PS | 1 |
Hider, RC | 1 |
Goddard, JG | 1 |
Thorniley, MS | 1 |
Green, CJ | 7 |
Fantini, GA | 1 |
Yoshioka, T | 1 |
Egri, L | 1 |
Stahl, GL | 2 |
Pan, HL | 1 |
Longhurst, JC | 2 |
Lelli, JL | 1 |
Pradhan, S | 1 |
Cobb, LM | 1 |
Salaris, SC | 1 |
Pham, J | 1 |
Ayene, IS | 1 |
al-Mehdi, AB | 1 |
Fisher, AB | 1 |
Messent, M | 1 |
Griffiths, MJ | 1 |
Quinlan, GJ | 1 |
Gutteridge, JM | 1 |
Evans, TW | 1 |
McAnulty, JF | 1 |
Huang, XQ | 1 |
Bailey, SM | 1 |
Reinke, LA | 1 |
Hung, TH | 1 |
Skepper, JN | 1 |
Burton, GJ | 1 |
Andrews, FJ | 1 |
Malcontenti, C | 1 |
O'Brien, PE | 1 |
Halliwell, B | 1 |
Kunz, R | 1 |
Schoenberg, MH | 1 |
Büchler, M | 1 |
Jost, K | 1 |
Beger, HG | 1 |
Drugas, GT | 1 |
Paidas, CN | 1 |
Yahanda, AM | 1 |
Ferguson, D | 1 |
Clemens, MG | 1 |
Baron, P | 1 |
Gomez-Marin, O | 1 |
Casas, C | 1 |
Heil, J | 1 |
Will, N | 1 |
Condie, R | 1 |
Burke, B | 1 |
Najarian, JS | 1 |
Sutherland, DE | 1 |
Lutz, J | 1 |
Augustin, A | 1 |
Friedrich, E | 1 |
Zimmerman, BJ | 1 |
Grisham, MB | 3 |
Granger, DN | 3 |
Healing, G | 7 |
Fuller, BJ | 5 |
Perler, BA | 1 |
Tohmeh, AG | 1 |
Bulkley, GB | 1 |
Simpkin, S | 4 |
Gower, J | 2 |
Green, C | 2 |
Omar, R | 1 |
Nomikos, I | 1 |
Piccorelli, G | 1 |
Savino, J | 1 |
Agarwal, N | 1 |
Dhami, L | 1 |
Prasad, S | 1 |
Shurey, C | 1 |
Hernandez, LA | 1 |
Lunec, J | 3 |
Paller, MS | 1 |
Hedlund, BE | 1 |
Fuller, B | 1 |
Smith, SM | 1 |
Manci, EA | 1 |
Kvietys, PR | 1 |
White, BC | 1 |
Krause, GS | 1 |
Aust, SD | 1 |
Eyster, GE | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes[NCT03085771] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | ||
Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations[NCT04333550] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2020-04-30 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for deferoxamine and Ischemia
Article | Year |
---|---|
Therapeutic angiogenesis for patients with limb ischemia by utilization of fibrin meshwork. Pilot randomized controlled study.
Topics: Adult; Deferoxamine; Drug Therapy, Combination; Feasibility Studies; Fibrin; Fibrinogen; Humans; Inj | 2003 |
66 other studies available for deferoxamine and Ischemia
Article | Year |
---|---|
A Composite Deferoxamine/Black Phosphorus Nanosheet/Gelatin Hydrogel Scaffold for Ischemic Tibial Bone Repair.
Topics: Animals; Bone Regeneration; Deferoxamine; Fracture Healing; Gelatin; Hydrogels; Ischemia; Nanostruct | 2022 |
Ferroptosis involved in sevoflurane-aggravated young rats brain injury induced by liver transplantation.
Topics: Animals; Brain Injuries; Child; Deferoxamine; Ferroptosis; Humans; Iron; Ischemia; Liver; Liver Tran | 2022 |
A carbon dot-based fluorescent nanoprobe for the associated detection of iron ions and the determination of the fluctuation of ascorbic acid induced by hypoxia in cells and in vivo.
Topics: Animals; Ascorbic Acid; Carbon; Cell Hypoxia; Deferoxamine; Fluorescent Dyes; Hep G2 Cells; Humans; | 2019 |
Ferroptosis occurs in phase of reperfusion but not ischemia in rat heart following ischemia or ischemia/reperfusion.
Topics: Animals; Biomarkers; Coenzyme A Ligases; Creatine Kinase; Deferoxamine; Ferroptosis; Iron; Ischemia; | 2021 |
Promotion of airway anastomotic microvascular regeneration and alleviation of airway ischemia by deferoxamine nanoparticles.
Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Chemokine CXCL12; Deferoxamine; Endothelial Cells; | 2014 |
Hypoxia-induced angiogenesis is increased by the controlled release of deferoxiamine from gelatin hydrogels.
Topics: Animals; Cell Hypoxia; Cells, Cultured; Deferoxamine; Delayed-Action Preparations; Endothelial Cells | 2014 |
Local injection of deferoxamine improves neovascularization in ischemic diabetic random flap by increasing HIF-1α and VEGF expression.
Topics: Animals; Cell Movement; Cell Survival; Deferoxamine; Diabetes Mellitus, Experimental; Dose-Response | 2014 |
DFO enhances the targeting of CD34-positive cells and improves neovascularization.
Topics: Animals; Antigens, CD34; Bone Marrow Cells; Cell Movement; Chemokine CXCL12; Chromones; Deferoxamine | 2015 |
Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
Topics: Adrenomedullin; Animals; Deferoxamine; Dose-Response Relationship, Drug; Hypoxia-Inducible Factor 1, | 2008 |
Mimic hypoxia improves angiogenesis in ischaemic random flaps.
Topics: Animals; Cell Survival; Cells, Cultured; Deferoxamine; Endothelial Cells; Fibroblasts; Ischemia; Mal | 2010 |
Inhibition of mitochondrial respiratory chain in the brain of rats after renal ischemia is prevented by N-acetylcysteine and deferoxamine.
Topics: Acetylcysteine; Animals; Cell Respiration; Deferoxamine; Disease Models, Animal; Drug Combinations; | 2010 |
Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function.
Topics: Animals; Apoptosis; Cell Proliferation; Deferoxamine; Endothelial Cells; Endothelium, Vascular; Hind | 2011 |
Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs.
Topics: Acute Disease; Acute Kidney Injury; Animals; Apoptosis; Deferoxamine; Female; Interleukin-6; Ischemi | 2012 |
Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2.
Topics: Acute Kidney Injury; Adoptive Transfer; Animals; Blood Urea Nitrogen; Cell Survival; Deferoxamine; D | 2012 |
Development of a thermoresponsive chitosan gel combined with human mesenchymal stem cells and desferrioxamine as a multimodal pro-angiogenic therapeutic for the treatment of critical limb ischaemia.
Topics: Angiogenesis Inducing Agents; Cell Movement; Cell Proliferation; Cells, Cultured; Chitosan; Deferoxa | 2012 |
Effect of deferoxamine and L-arginine treatment on lipid peroxidation in an intestinal ischaemia-reperfusion model in rats.
Topics: Animals; Arginine; Deferoxamine; Disease Models, Animal; Enzyme Inhibitors; Erythrocytes; Female; Gl | 2002 |
Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model.
Topics: Animals; Deferoxamine; Fibrin Tissue Adhesive; Iron Chelating Agents; Ischemia; Muscle, Skeletal; Ne | 2003 |
Deferoxamine reduces cold-ischemic renal injury in a syngeneic kidney transplant model.
Topics: Animals; Cold Temperature; Deferoxamine; Dose-Response Relationship, Drug; Iron Chelating Agents; Is | 2003 |
Deferoxamine-fibrin accelerates angiogenesis in a rabbit model of peripheral ischemia.
Topics: Animals; Blood Pressure; Collateral Circulation; Deferoxamine; Disease Models, Animal; Drug Therapy, | 2003 |
Inhibition of brain creatine kinase activity after renal ischemia is attenuated by N-acetylcysteine and deferoxamine administration.
Topics: Acetylcysteine; Animals; Antioxidants; Brain; Brain Diseases, Metabolic; Creatine Kinase; Deferoxami | 2008 |
Antioxidant defense and free radical production in a rabbit model of kidney ischemia-reperfusion.
Topics: Animals; Antioxidants; Catalase; Deferoxamine; Electron Spin Resonance Spectroscopy; Free Radicals; | 1995 |
Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth.
Topics: Adenocarcinoma; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cell Divisi | 1995 |
Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents.
Topics: Animals; Cell Hypoxia; Chelating Agents; Chelation Therapy; Deferoxamine; Diabetes Mellitus, Experim | 1995 |
Preservation of cortical microcirculation after kidney ischemia-reperfusion: value of an iron chelator.
Topics: Animals; Deferoxamine; Ischemia; Kidney Cortex; Microcirculation; Rabbits; Renal Circulation; Reperf | 1995 |
The in vivo cytoprotection of ascorbic acid against ischemia/reoxygenation injury of rat liver.
Topics: Adenosine Triphosphate; Alanine Transaminase; Animals; Ascorbic Acid; Aspartate Aminotransferases; D | 1995 |
Preliminary results of deferoxamine and L1 treatment of spinal cord ischemia.
Topics: Animals; Deferiprone; Deferoxamine; Dogs; Iron Chelating Agents; Ischemia; Pyridones; Reperfusion In | 1995 |
Preservation of cortical microcirculation after kidney ischemia-reperfusion: value of an iron chelator.
Topics: Animals; Constriction; Deferoxamine; Ischemia; Kidney Cortex; Laser-Doppler Flowmetry; Microcirculat | 1994 |
Direct evidence of free radical production after ischaemia and reperfusion and protective effect of desferrioxamine: ESR and vitamin E studies.
Topics: Animals; Deferoxamine; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Free | 1994 |
Activation of Kupffer cells and neutrophils for reactive oxygen formation is responsible for endotoxin-enhanced liver injury after hepatic ischemia.
Topics: Animals; Antibodies, Monoclonal; CD11 Antigens; Chromans; Deferoxamine; Gadolinium; Ischemia; Kupffe | 1995 |
Protection of the transiently ischemic cat retina by zinc-desferrioxamine.
Topics: Animals; Cats; Deferoxamine; Electroretinography; Fundus Oculi; Hydroxybenzoates; Hydroxyl Radical; | 1994 |
The effect of a synthetic hexadentate iron chelator (CP130) and desferrioxamine on rabbit kidneys exposed to cold and warm ischaemia.
Topics: Animals; Deferoxamine; Iron Chelating Agents; Ischemia; Kidney; Lipid Peroxidation; Male; Pyridones; | 1993 |
Mobilization of low-molecular-weight iron and peroxidative damage during ischemia and reoxygenation of the rat liver.
Topics: Alanine Transaminase; Analysis of Variance; Animals; Aspartate Aminotransferases; Deferoxamine; Iron | 1994 |
Deferoxamine prevents lipid peroxidation and attenuates reoxygenation injury in postischemic skeletal muscle.
Topics: Animals; Deferoxamine; Electrophysiology; Hindlimb; Ischemia; Lipid Peroxides; Male; Muscles; Rats; | 1993 |
[Examination of the reperfusion damage to a striated muscle: possible pathomechanism and prevention].
Topics: Animals; Catalase; Deferoxamine; Drug Evaluation, Preclinical; Ischemia; Methylprednisolone; Muscles | 1993 |
Activation of ischemia- and reperfusion-sensitive abdominal visceral C fiber afferents. Role of hydrogen peroxide and hydroxyl radicals.
Topics: Abdomen; Action Potentials; Animals; Cats; Deferoxamine; Free Radicals; Hydrogen Peroxide; Hydroxide | 1993 |
Prevention of postischemic injury in immature intestine by deferoxamine.
Topics: Animals; Constriction; Deferoxamine; Intestines; Ischemia; Male; Mesenteric Arteries; Rats; Rats, Sp | 1993 |
Traumatic versus postischemic induction of oxidative stress in rat liver.
Topics: Animals; Calcimycin; Deferoxamine; Ischemia; Liver; Male; Malondialdehyde; Organ Culture Techniques; | 1993 |
Inhibition of lung tissue oxidation during ischemia/reperfusion by 2-mercaptopropionylglycine.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Deferoxamine; Ischemia; Lipid Peroxidation; Lung; Male; Ox | 1993 |
Ischaemia--reperfusion injury in the rat is modulated by superoxide generation and leads to an augmentation of the hypoxic pulmonary vascular response.
Topics: Animals; Arginine; Catalase; Deferoxamine; Ischemia; Linolenic Acids; Lung; Male; NG-Nitroarginine M | 1996 |
The efficacy of antioxidants administered during low temperature storage of warm ischemic kidney tissue slices.
Topics: Animals; Antioxidants; Ascorbic Acid; Chromans; Cryopreservation; Deferoxamine; Ischemia; Kidney Cor | 1997 |
Ischemia-reperfusion injury of rabbit kidney: comparative effects of desferrioxamine and N-acetylcysteine as antioxidants.
Topics: Acetylcysteine; Animals; Antioxidants; Aspartate Aminotransferases; Deferoxamine; Glutathione; Ische | 2000 |
Antioxidants and gadolinium chloride attenuate hepatic parenchymal and endothelial cell injury induced by low flow ischemia and reperfusion in perfused rat livers.
Topics: Animals; Antioxidants; Blood Flow Velocity; Catalase; Deferoxamine; Endothelium, Vascular; Gadoliniu | 2000 |
In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies.
Topics: Aldehydes; Cyclic N-Oxides; Deferoxamine; Female; Fluorescent Antibody Technique; Heat-Shock Protein | 2001 |
Iron contributes to endothelial dysfunction in acute ischemic syndromes.
Topics: Acute Disease; Coronary Circulation; Coronary Disease; Deferoxamine; Endothelial Growth Factors; End | 2002 |
Sequence of gastric mucosal injury following ischemia and reperfusion. Role of reactive oxygen metabolites.
Topics: Allopurinol; Animals; Catalase; Deferoxamine; Free Radicals; Gastric Mucosa; Ischemia; Male; Oxygen; | 1992 |
Hydrogen peroxide-induced cardiovascular reflexes. Role of hydroxyl radicals.
Topics: Animals; Aspirin; Blood Pressure; Cardiovascular Physiological Phenomena; Cardiovascular System; Cat | 1992 |
Oxygen radicals in liver ischemia and reperfusion--experimental data.
Topics: Allopurinol; Animals; Deferoxamine; Electron Spin Resonance Spectroscopy; Fatty Acids, Nonesterified | 1991 |
Conjugated desferoxamine attenuates hepatic microvascular injury following ischemia/reperfusion.
Topics: Animals; Blood Vessels; Deferoxamine; Ischemia; Liver Circulation; Male; Microcirculation; Rats; Rat | 1991 |
Renal preservation after warm ischemia using oxygen free radical scavengers to prevent reperfusion injury.
Topics: Animals; Ceruloplasmin; Creatinine; Deferoxamine; Dogs; Free Radical Scavengers; Hot Temperature; Is | 1991 |
Severity of oxygen free radical effects after ischemia and reperfusion in intestinal tissue and the influence of different drugs.
Topics: Allopurinol; Animals; Catalase; Deferoxamine; Free Radicals; Hemoglobins; Intestinal Mucosa; Intesti | 1990 |
Role of oxidants in ischemia/reperfusion-induced granulocyte infiltration.
Topics: Animals; Catalase; Cats; Chemotaxis, Leukocyte; Deferoxamine; Dimethyl Sulfoxide; Granulocytes; Hydr | 1990 |
Iron redistribution and lipid peroxidation in the cold ischaemic kidney.
Topics: Animals; Cold Temperature; Deferoxamine; In Vitro Techniques; Iron; Ischemia; Kidney; Kidney Cortex; | 1990 |
Inhibition of the compartment syndrome by the ablation of free radical-mediated reperfusion injury.
Topics: Allopurinol; Animals; Blood Pressure; Compartment Syndromes; Deferoxamine; Free Radicals; Ischemia; | 1990 |
Protection against oxidative damage in cold-stored rabbit kidneys by desferrioxamine and indomethacin.
Topics: Animals; Cold Temperature; Deferoxamine; In Vitro Techniques; Indomethacin; Ischemia; Kidney; Kidney | 1989 |
Measurement by HPLC of desferrioxamine-available iron in rabbit kidneys to assess the effect of ischaemia on the distribution of iron within the total pool.
Topics: Animals; Chromatography, High Pressure Liquid; Cytosol; Deferoxamine; Iron; Ischemia; Kidney; Kidney | 1989 |
Prevention of postischaemic lipid peroxidation and liver cell injury by iron chelation.
Topics: Animals; Deferoxamine; Ischemia; Lipid Peroxidation; Liver; Male; Rats; Rats, Inbred Strains; Reperf | 1989 |
The effect of desferrioxamine on lipid peroxidation and survival of ischaemic island skin flaps in rats.
Topics: Animals; Deferoxamine; Female; Graft Survival; Ischemia; Lipid Peroxidation; Necrosis; Rats; Rats, I | 1989 |
A role for iron in oxidant-mediated ischemic injury to intestinal microvasculature.
Topics: Animals; Apoproteins; Capillaries; Capillary Permeability; Cats; Deferoxamine; Free Radicals; Hydrox | 1987 |
Reduced susceptibility to lipid peroxidation in cold ischemic rabbit kidneys after addition of desferrioxamine, mannitol, or uric acid to the flush solution.
Topics: Animals; Deferoxamine; Freezing; Glutathione; Glutathione Disulfide; Ischemia; Kidney; Lipid Peroxid | 1986 |
Role of iron in postischemic renal injury in the rat.
Topics: Animals; Deferoxamine; Edetic Acid; Free Radicals; Glomerular Filtration Rate; Iron; Ischemia; Kidne | 1988 |
The post treatment experiment: an operational definition of reperfusion injury.
Topics: Allopurinol; Animals; Creatine Kinase; Deferoxamine; Disease Models, Animal; Heart Arrest; Ischemia; | 1988 |
Lipid peroxidation in the cortex and medulla of rabbit kidneys subjected to cold ischaemia and the value of protective agents.
Topics: Animals; Cold Temperature; Deferoxamine; Imidazoles; In Vitro Techniques; Indomethacin; Ischemia; Ki | 1987 |
Reduction of susceptibility to lipid peroxidation by desferrioxamine in rabbit kidneys subjected to 24-hour cold ischemia and reperfusion.
Topics: Animals; Cold Temperature; Deferoxamine; Free Radicals; Ischemia; Kidney Transplantation; Lipid Pero | 1987 |
Gastric mucosal injury in the rat. Role of iron and xanthine oxidase.
Topics: Animals; Chromium Radioisotopes; Deferoxamine; Erythrocytes; Free Radicals; Gastric Mucosa; Iron; Is | 1987 |
Desferrioxamine reduces susceptibility to lipid peroxidation in rabbit kidneys subjected to warm ischaemia and reperfusion.
Topics: Animals; Deferoxamine; Ischemia; Kidney; Kinetics; Lipid Peroxides; Perfusion; Rabbits; Renal Circul | 1986 |
Postischemic tissue injury by iron-mediated free radical lipid peroxidation.
Topics: Calcium; Cell Membrane; Deferoxamine; Free Radicals; Humans; Iron; Ischemia; Lipid Peroxides; Mitoch | 1985 |